Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Bio-Rad Laboratories, Inc.
  6. Summary
    BIO   US0905722072

BIO-RAD LABORATORIES, INC.

(BIO)
  Report
Delayed Nyse  -  04:04:04 2023-01-27 pm EST
478.96 USD   +0.64%
01/10Transcript : Bio-Rad Laboratories, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 04:30 PM
CI
01/10Bio-rad Laboratories, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/06Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
467.04(c) 457(c) 456.69(c) 475.91(c) 478.96 Last
126 149 142 022 107 277 199 792 132 984 Volume
+2.13% -2.15% -0.07% +4.21% +0.64% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 821 M - -
Net income 2022 -3 660 M - -
Net cash position 2022 4 268 M - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 2 903 M - -
Net income 2023 458 M - -
Net cash position 2023 4 758 M - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 13 908 M 13 908 M -
EV / Sales 2022 3,42x
EV / Sales 2023 3,15x
Nbr of Employees 7 900
Free-Float 70,5%
More Financials
Company
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.9%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents,... 
Read more
More about the company
Ratings of Bio-Rad Laboratories, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIO-RAD LABORATORIES, INC.
01/10Transcript : Bio-Rad Laboratories, Inc. Presents at 41st Annual J.P. Morgan H..
CI
01/10Bio-rad Laboratories, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
01/06Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, Febr..
BU
01/04Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
BU
2022RBC Initiates Bio-Rad Laboratories at Outperform, Sets Price Target at $565, Cites Reve..
MT
2022Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms
AQ
2022Transcript : Bio-Rad Laboratories, Inc. Presents at Credit Suisse 31st Annual..
CI
2022Bio-rad Laboratories, Inc. : Regulation FD Disclosure (form 8-K)
AQ
2022Bio-Rad Laboratories, Inc. and NuProbe USA Enter Into an Exclusive Licensing Agreement ..
CI
2022Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C..
AQ
2022Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C..
BU
2022BIO-RAD LABORATORIES, INC. Management's Discussion and Analysis of Financial Condition..
AQ
2022Bio-Rad Laboratories Posts Lower Q3 Net Income, Revenue; Shares Fall Friday
MT
2022Credit Suisse Adjusts Bio-Rad Laboratories' Price Target to $640 From $715, Keeps Outpe..
MT
2022Bio-rad : Q3 Earnings Snapshot
AQ
More news
News in other languages on BIO-RAD LABORATORIES, INC.
2022COMPANY TALK/Qiagen-Fusionsgerüchte anscheinend ohne Grundlage
2022Bio-Rad Laboratories, Inc. et NuProbe USA concluent un accord de licence exclusif pour ..
2022Bio-Rad Laboratories affiche un revenu net et des recettes inférieurs au troisième trim..
2022Bio-Rad Laboratories, Inc. fournit des prévisions de bénéfices pour l'année 2022
2022Bio-Rad Laboratories, Inc. annonce ses résultats pour le troisième trimestre et les neu..
More news
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
More recommendations
ETFs positioned on BIO-RAD LABORATORIES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ETFMG Treatments Testing and Advancements E...3.67%2.23%-NC
Janus Small/Mid Cap Growth Alpha ETF - USD2.98%2.72%United_States
First Trust AlphaDEX U.S. Health Care Secto...1.9%0.50%-United_States
Invesco S&P 500� Equal Weight H...1.41%1.70%United_States
BMO Equal Weight US Health Care Index ETF - CAD1.41%0.16%United_States
More ETFs positioned on BIO-RAD LABORATORIES, INC.
Chart BIO-RAD LABORATORIES, INC.
Duration : Period :
Bio-Rad Laboratories, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 478,96 $
Average target price 588,75 $
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Norman D. Schwartz Chairman, President & Chief Executive Officer
Ilan Daskal Chief Financial Officer & Executive Vice President
Andrew J. Last Chief Operating Officer & Executive Vice President
Jeffrey L. Edwards Independent Director
Gregory K. Hinckley Chief Financial Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIO-RAD LABORATORIES, INC.13.18%13 832
ABBOTT LABORATORIES1.10%193 659
MEDTRONIC PLC4.48%108 862
BECTON, DICKINSON AND COMPANY-2.96%70 823
DEXCOM, INC.-8.16%41 194
HOYA CORPORATION14.64%39 807